Biomarkers and drug development 2009

Bibliography

• Sultana SR, Roblin D, O'Connell D. Translational research in the pharmaceutical industry: from theory to reality. Drug Discov Today 2007;12:419-25
   PubMed Web of Science ®Google Scholar
• Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy 2006;26:601-8
   PubMed Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5
   PubMed Web of Science ®Google Scholar
• Keesee SK. Molecular diagnostics: impact upon cancer detection. Expert Rev Mol Diagn 2002;2:91-2
   PubMedGoogle Scholar
• Poste G. Molecular diagnostics: a powerful new component of the healthcarevalue chain. Expert Rev Mol Diagn 2001;1:1-5
   PubMedGoogle Scholar
• Leonard DG. The present and future of molecular diagnostics. Mol Diagn 2001;6:71-2
   PubMedGoogle Scholar
• Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26
   PubMed Web of Science ®Google Scholar
• O'Dwyer ME, Druker BJ. STI571: an inhibitor of the BCR-ABL tyrosinekinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol 2000;1:207-11
   PubMedGoogle Scholar
• Ross JS, Ginsburg GS. Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care. Drug Discov Today 2002;7(16):859-64
   PubMed Web of Science ®Google Scholar
• Wilson LE, Gallant JE. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations. Clin Infect Dis 2009;48(2):214-21
   PubMed Web of Science ®Google Scholar
• Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003;3:912-20
   PubMed Web of Science ®Google Scholar
• Johnson JA. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet 2003;19:660-6. [Review]
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529-37
   PubMed Web of Science ®Google Scholar
• Desai AA, Innocenti F, Ratain MJ. Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene 2003;22:6621-8
   PubMed Web of Science ®Google Scholar
• Iqbal S, Lenz HJ. Targeted therapy and pharmacogenomic programs. Cancer 2003;97(8 Suppl):2076-82
   PubMed Web of Science ®Google Scholar
• Taylor JG, Choi EH, Foster CB, et al. Using genetic variation to study human disease. Trends Mol Med 2001;7:507-12
   PubMed Web of Science ®Google Scholar
• Carlson CS, Newman TL, Nickerson DA. SNPing in the human genome. Curr Opin Chem Biol 2001;5:78-85
   PubMed Web of Science ®Google Scholar
• Griffin TJ, Smith LM. Single-nucleotide polymorphism analysis by MALDI TOF mass spectrometry. Trends Biotechnol 2000;18:77-84
   PubMed Web of Science ®Google Scholar
• Pusztai L, Ayers M, Stec J, et al. Clinical application of cDNA microarrays in oncology. Oncologist 2003;8:252-8
   PubMed Web of Science ®Google Scholar
• Macgregor PF. Gene expression in cancer: the application of microarrays. Expert Rev Mol Diagn 2003;3:185-200
   PubMed Web of Science ®Google Scholar
• Kallioniemi OP. Biochip technologies in cancer research. Ann Med 2001;33:142-7
   PubMed Web of Science ®Google Scholar
• The International Hap\Map Project. Available from: http://snp.cshl.org/
   Google Scholar
• Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nature Rev Cancer 2001;1:99-108
   PubMed Web of Science ®Google Scholar
• Borg A. Molecular and pathological characterization of inherited breast cancer. Semin Cancer Biol 2001;11:375-85
   PubMed Web of Science ®Google Scholar
• Renegar G, Rieser P, Manasco P. Pharmacogenetics: the Rx perspective. Expert Rev Mol Diagn 2001;1:255-63
   PubMedGoogle Scholar
• Jass J. Familial colorectal cancer: pathology and molecular characteristics. Lancet Oncol 2000;1:220-6
   PubMedGoogle Scholar
• Weber W, Estoppey J, Stoll H. Familial cancer diagnosis. Anticancer Res 2001;21:3631-5
   PubMed Web of Science ®Google Scholar
• Calzone KA, Biesecker BB. Genetic testing for cancer predisposition. Cancer Nurs 2002;25:15-25
   PubMed Web of Science ®Google Scholar
• Ingelman-sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 2001;482:11-9
   PubMed Web of Science ®Google Scholar
• Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 2002;315:137-55
   PubMed Web of Science ®Google Scholar
• Nebert DW, Dieter M. The evolution of drug metabolism. Pharmacology 2000;61:124-35
   PubMed Web of Science ®Google Scholar
• Relling MV. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91:2001-8
   PubMed Web of Science ®Google Scholar
• McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus: implications for clinical pharmacogenomics. Pharmacogenomics 2002;3:89-8
   PubMed Web of Science ®Google Scholar
• Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 2002;3:485-92
   PubMed Web of Science ®Google Scholar
• Iyer L. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002;2:43-7
   PubMedGoogle Scholar
• Roses AD. Pharmacogenetics. Hum Mol Genet 2001;10:2261-7
   PubMed Web of Science ®Google Scholar
• Linder MW, Valdes R. Genetic mechanisms for variability in drug response and toxicity. J Anal Toxicol 2001;25:405-13
   PubMed Web of Science ®Google Scholar
• Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev Genet 2003;4:937-47
   PubMed Web of Science ®Google Scholar
• Danesi R, De Braud F, Fogli S, et al. Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol Sci 2001;22:420-6
   PubMed Web of Science ®Google Scholar
• Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001;1:65-70
   PubMedGoogle Scholar
• Stoehlmacher J. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001;21:3075-9
   PubMed Web of Science ®Google Scholar
• Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999;353:2195-9
   PubMed Web of Science ®Google Scholar
• Rusnak JM, Kisabeth RM, Herbert DP, et al. Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care. Mayo Clin Proc 2001;76:299-309
   PubMed Web of Science ®Google Scholar
• Hess P, Cooper D. Impact of pharmacogenomics on the clinical laboratory. Mol Diagn 1999;4:289-98
   PubMedGoogle Scholar
• Harkin DP. Uncovering functionally relevant signaling pathways using microarray based expression profiling. Oncologist 2000;5:501-7
   PubMedGoogle Scholar
• Snijders AM, Meijer GA, Brakenhoff RH, et al. Microarray techniques in pathology: tool or toy? Mol Pathol 2000;53:289-94
   PubMedGoogle Scholar
• Raetz EA, Moos PJ, Szabo A, et al. Methods and clinical applications in oncology. Hematol Oncol Clin North Am 2001;15:911-30
   PubMed Web of Science ®Google Scholar
• Polyak K, Riggins GJ. Gene discovery using the serial analysis of gene expression technique: implications for cancer research. J Clin Oncol 2001;19:2948-58
   PubMed Web of Science ®Google Scholar
• Lewis F, Maughan NJ, Smith V, et al. Unlocking the archive gene expression in paraffin-embedded tissue. J Pathol 2001;195:66-71
   PubMed Web of Science ®Google Scholar
• Maughan NJ, Lewis FA, Smith V. An introduction to arrays. J Pathol 2001;195:3-6
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Ross DT, Perou CM, et al. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 2001;195:41-52
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin Oncol 2002;20:1932-41
   PubMed Web of Science ®Google Scholar
• Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-70
   PubMed Web of Science ®Google Scholar
• Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-93
   PubMed Web of Science ®Google Scholar
• Chang JC, Wooten EC, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9
   PubMed Web of Science ®Google Scholar
• Hamadeh HK, Bushel P, Paules R, et al. Discovery in toxicology: mediation by gene expression array technology. J Biochem Mol Toxicol 2001;15:231-42
   PubMed Web of Science ®Google Scholar
• Fielden MR, Zacharewski TR. Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology. Toxicol Sci 2001;60:6-10
   PubMed Web of Science ®Google Scholar
• Burchiel SW, Knall CM, Davis JW, et al. Analysis of genetic and epigenetic mechanisms of toxicity: potential roles of toxicogenomics and proteomics in toxicology. Toxicol Sci 2001;59:193-5
   PubMed Web of Science ®Google Scholar
• Hamadeh HK, Amin RP, Paules RS, Afshari CA. An overview of toxicogenomics. Curr Issues Mol Biol 2002;4:45-56
   PubMedGoogle Scholar
• Mitcheson JS, Chen J, Lin M, et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000;97:12329-33
   PubMed Web of Science ®Google Scholar
• Shockcor JP, Holmes E. Metabonomic applications in toxicity screening and disease diagnosis. Curr Top Med Chem 2002;2:35-51
   PubMedGoogle Scholar
• Nicholson JK, Wilson ID. Opinion: understanding ‘global’ systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov 2003;2:668-76
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Connelly J, Lindon JC, et al. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002;1:153-61
   PubMed Web of Science ®Google Scholar
• Witzmann FA, Grant RA. Pharmacoproteomics in drug development. Pharmacogenomics J 2003;3:69-76
   PubMed Web of Science ®Google Scholar
• Steiner S, Aicher L, Raymackers J, et al. Cyclosporine A decreases the protein level of the calcium-binding protein calbindin-D 28 kDa in rat kidney. Biochem Pharmacol 1996;51:253-8
   Google Scholar
• Steiner S, Gatlin CL, Lennon JJ, et al. Proteomics to display lovastatin-induced protein and pathway regulation in rat liver. Electrophoresis 2000;21:2129-37
   PubMed Web of Science ®Google Scholar
• Moller A, Malerczyk C, Volker U, et al. Monitoring daunorubicin-induced alterations in protein expression in pancreas carcinoma cells by two-dimensional gel electrophoresis. Proteomics 2002;2:697-705
   PubMed Web of Science ®Google Scholar
• Zhou H, Ranish JA, Watts JD, et al. Quantitative proteome analysis by solid-phase isotope tagging and mass spectrometry. Nat Biotechnol 2002;20:12-515
   Google Scholar
• Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7
   PubMed Web of Science ®Google Scholar
• Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas-pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002;62:1868-75
   PubMed Web of Science ®Google Scholar
• Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-1304
   PubMed Web of Science ®Google Scholar
• McClellan M. FDA Commissioner Says Science is Far From Eliminating Cancer as a Threat. The Cancer Letter 2004;30:1-3
   Google Scholar
• Johnson JR, Williams G, Pazdur R. End Points and United States Food and Drug Administration Approval of Oncology Drugs. J Clinical Oncology 2003;21:1404-11
   PubMed Web of Science ®Google Scholar
• Lesko LJ, Atkinson AJ. Use of Biomarkers and Surrogate Endpoints in Drug Development and Regulatory Decision Making: Criteria, Validation, Strategies. Annu Rev Pharmacol Toxicol 2001;41:347-66
   PubMed Web of Science ®Google Scholar
• Johnson JR, Williams G, Pazdur R. End Points and United States Food and Drug Administration Approval of Oncology Drugs. J Clinical Oncology 2003;21:1404-11
   PubMed Web of Science ®Google Scholar
• Pisano DJ, Mantus D. FDA Regulatory Affairs. Boca Raton, FL: CRC Press, 2004
   Google Scholar
• FDA Guidance for industry. Pharmacogenomics data submissions. Federal Register Notice 2003;68:62461-3
   Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework. Clin Pharmacol Ther 2001;69:89-95
   PubMed Web of Science ®Google Scholar